In a significant legal move, Texas Attorney General Ken Paxton has filed a lawsuit against Kenvue, the maker of Tylenol, alleging that the company concealed potential risks associated with its widely used pain reliever. The lawsuit claims that Kenvue engaged in deceptive marketing practices regarding the safety of acetaminophen, particularly for pregnant women, despite ongoing assertions from the medical community that Tylenol is safe for use during pregnancy 1, 2, 6.
The lawsuit, filed in a Texas district court, comes amid a growing public discourse surrounding the safety of acetaminophen and its alleged links to autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Paxton’s claims echo controversial assertions made by public figures, including former President Donald Trump and Robert F. Kennedy Jr., who have previously suggested a connection between acetaminophen use during pregnancy and developmental disorders in children 3, 5, 8.
In his filing, Paxton argues that Kenvue has misled consumers by not adequately disclosing the potential risks associated with the use of Tylenol during pregnancy. He contends that the company has prioritized profits over public safety, thereby violating Texas consumer protection laws. “The evidence shows that Kenvue has known for years about the potential risks of acetaminophen use during pregnancy but chose to hide that information from consumers,” Paxton stated 4, 6.
Kenvue, which was spun off from Johnson & Johnson, has firmly rejected the allegations, asserting that the claims lack legal merit and scientific support. The company maintains that extensive research has consistently shown that acetaminophen is safe for use during pregnancy when taken as directed. “We are committed to defending our product and the science that supports its safety,” a Kenvue spokesperson said in response to the lawsuit 2, 6.
The legal action comes on the heels of a recent update from U.S. Health Secretary Robert F. Kennedy Jr., who advised pregnant women to reconsider their use of acetaminophen, further fueling the debate surrounding the drug’s safety 4. This guidance has been met with skepticism by many in the medical community, who argue that the existing body of research does not support claims linking acetaminophen to autism or ADHD.
The lawsuit has drawn attention not only for its implications for Kenvue but also for its potential impact on public health messaging regarding pain relief during pregnancy. Experts warn that the spread of misinformation could lead to unnecessary anxiety among expectant mothers, potentially causing them to avoid necessary pain management options 1, 3.
Critics of the lawsuit argue that it may be politically motivated, given Paxton’s aspirations for a U.S. Senate seat. Some observers have noted that the timing of the lawsuit aligns with a broader trend of politicizing health issues, particularly those related to maternal and child health 8.
The legal landscape surrounding acetaminophen is complex, with various studies yielding mixed results regarding its safety profile. A notable study published in 2023 examined a cohort of 2,644 mother-child pairs and sought to clarify the relationship between prenatal acetaminophen use and the development of ASD and ADHD. While the study found some associations, it also highlighted the need for further research to establish causality 7.
As the lawsuit unfolds, it is likely to reignite discussions about the regulation of over-the-counter medications and the responsibilities of pharmaceutical companies in communicating risks to consumers. The outcome could set a precedent for how similar cases are handled in the future, particularly as more states consider taking legal action against drug manufacturers over safety claims.
In the meantime, the public remains divided on the issue. Some parents express concern over the potential risks associated with acetaminophen, while others advocate for its continued use, citing its long-standing safety record. As the legal battle progresses, the implications for public health and consumer trust in pharmaceutical companies will be closely monitored.
As Texas moves forward with its lawsuit against Kenvue, the case serves as a reminder of the ongoing complexities surrounding medication safety, consumer protection, and the intersection of health and politics in America. The outcome may not only affect the future of Tylenol but could also reshape the landscape of maternal health guidelines and the pharmaceutical industry’s approach to risk communication.
